About: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI<2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs. In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients.
  • We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI<2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs. In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients. (en)
Title
  • Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma
  • Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma (en)
skos:prefLabel
  • Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma
  • Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma (en)
skos:notation
  • RIV/00098892:_____/10:#0000398!RIV13-MZ0-00098892
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(NR9500)
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 292619
http://linked.open...ai/riv/idVysledku
  • RIV/00098892:_____/10:#0000398
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • myeloma, prognostication, proliferative index, biological therapy (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • SK - Slovenská republika
http://linked.open...ontrolniKodProRIV
  • [07E79F025D92]
http://linked.open...i/riv/nazevZdroje
  • Neoplasma
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 57
http://linked.open...iv/tvurceVysledku
  • Minařík, Jiří
  • Zemanová, Markéta
issn
  • 0028-2685
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software